Regione Lombardia PROCEDURE FOR THE DECLARATION OF MOBILITY

•

On 27^th February 2009, Assolombarda, on behalf of Cell Therapeutics Inc., started the procedure under Articles 4 and 24 of Law no. 223/91 for the collective dismissal of all of the 56 employees working at the production site of Bresso (Milan);

Such procedure was necessary for the reasons explained in the notice of commencement of said procedure;

During the course of the meetings with the Trade Unions no agreement was reached;

•

On 14^th April 2009, Assolombarda, on behalf of the Company, gave to the Regional Agency for Education, Training, and Employment notice of the failure to reach an agreement; and

The Regional Agency for Education, Training, and Employment has convened the parties today

•

To implement the procedura di mobilità involving a maximum of 56 employees; the agreement sets out the criteria of selection of the personnel to be involved in the procedure and defines the departure from Art. 8, paragraph 4, of Law no. 236/93, fixing 17^th May 2010 as the deadline;

•

To implement the CIGS procedure due to company’s crisis arising from the total closing down of business, pursuant to Art. 1 of Law no. 223/91 and Art. 2 of Ministerial Decree no. 31826/02, involving a maximum of 56 employees, effective from 18^th May 2009, for a term of 12 months, with the implementation of a plan to handle redundancies; and

To exclude rotation with regard to the employees involved in the CIGS procedure.

/s/ Christina Ann Waters

President, Cell Therapeutics Europe (CTE)

/s/ Luca Morelli

/s/ Stefania Cerioni

CTI Bresso Employee and

CTI’s Union Representative

/s/ Giancarlo Lombardo

/s/ Paolo Pavesi

CTI Bresso Employee and

Employee Representative to Union

/s/ Paola Nicoli

CTI Bresso Employee and

Employee Representative to Union

/s/ Rosanna Cavagnoli

CTI Bresso Employee and

Employee Representative to Union

/s/ Carlo Alberto Balzarini

•

On 27^th February 2009, the Company started, through Assolombarda, the procedure under Articles 4 and 24 of Law no. 223/91 for the collective dismissal of all of the 56 employees working at the Bresso branch due to the definitive and total closing down of the business;

During the meetings held between the Parties, in compliance with the provisions set forth in Art. 4, paragraph 5, of Law no. 223/1991, the reasons for such measure were thoroughly examined, as detailed in the notice of commencement of the procedure, the content of which must be deemed as if entirely transcribed herein;

In such context, the Parties examined the advisability of implementing the CIGS procedure (among other reasons) to facilitate the start-up, if any, of a business to safeguard the company activities and consequently offer re-employment opportunities;

Today the Parties have signed an agreement concerning the management of the employees declared redundant

4.

The amount referred to under point 2 above shall be increased by 3 additional monthly instalments of the applicable gross CIGS ceiling if, on 31^st July 2009, the conditions for the continuation of the business activity suitable to permit the re-employment of the redundant personnel, through the raising of funds and the set-up of a suitable corporate vehicle, are not fulfilled.

President, Cell Therapeutics

Europe (CTE)

•

On 27^th February 2009, the Company started, through Assolombarda, the procedure under Articles 4 and 24 of Law no. 223/91 for the collective dismissal of all of the 56 employees working at the Bresso branch due to the definitive and total closing down of the business;

During the meetings held between the Parties, in compliance with the provisions set forth in Art. 4, paragraph 5, of Law no. 223/1991, the reasons for such measure were thoroughly examined, as detailed in the notice of commencement of the procedure, the content of which must be deemed as if entirely transcribed herein;

In such context, the Parties examined the advisability of implementing the CIGS procedure (among other reasons) to facilitate the start-up, if any, of a business to safeguard the company activities and consequently offer re-employment opportunities

3.

In order to facilitate the procedure referred to in the recitals, and as an alternative to the immediate implementation of the mobility plan referred to in the company notice dated 27^th February 2009, the Parties hereby agree to implement the CIGS procedure due to the closing down of the business, pursuant to Ministerial Decree dated 18^th December 2002, effective from 18^th May 2009, for a total of 12 months. The 56 employees will be suspended based on the technical and organisational needs connected with the closing down of the business and the necessary consequent interventions. For the grounds connected with the reasons for implementing the CIGS procedure, as detailed herein, the Parties acknowledge that there do not exist the conditions for the rotation of the personnel involved in the suspension, it being a closing down of business.

President, Cell Therapeutics

Europe (CTE)

CTI Bresso Employee and

Employee Representative to Union

CTI Bresso Employee and

Employee Representative to Union

CTI Bresso Employee and

Employee Representative to Union